The incidence of new onset diabetes after transplant (NODAT) has increased over the past decade, likely due to calcineurin inhibitor-based immunosuppressants, including tacrolimus (TAC) and cyclosporin (CsA). Voclosporin (VCS), a next generation calcineurin inhibitor is reported to cause fewer incidences of NODAT but the reason is unclear. Whilst calcineurin signaling plays important roles in pancreatic beta-cell survival, proliferation, and function, its effects on human beta-cells remain understudied. In particular, we do not understand why some calcineurin inhibitors have more profound effects on the incidence of NODAT. Here, we compared the the effects of TAC and VCS on the transcriptomic profile of human islets. SOURCE: James Johnson (james.d.johnson@ubc.ca) -  University of British Columbia

Pluto Bioinformatics

GSE156903: Differential effects of voclosporin and tacrolimus on insulin secretion from human islets